Breast Cancer Clinical Trial
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
Summary
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
Eligibility Criteria
Inclusion Criteria:
Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen.
Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen.
at least one measurable lesion
Exclusion Criteria:
More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease.
Previous hormonotherapy for advanced disease other than Tamoxifen.
Myocardial infarction within previous 6 mo
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Dallas Texas, 75204, United States
Antwerpen , 2020, Belgium
Bruxelles , 1000, Belgium
Leuven , 3000, Belgium
Namur , 5000, Belgium
Wilrijk , 2610, Belgium
Porto Alegre RS, 90610, Brazil
Sao Paulo SP, 01509, Brazil
Sydney Nova Scotia, B1P 1, Canada
Bogota Bogota . DC, , Colombia
Cali , , Colombia
Hyderabad Andhra Pradesh, 500 0, India
Bangalore Karnataka, 560 0, India
Mumbai Maharashtra, 400 0, India
Pune Maharashtra, 41101, India
Mexico Distrito Federal, 07760, Mexico
Guadalajara Jalisco, 44280, Mexico
Lima , 11, Peru
Lima , 34, Peru
Manila , 1000, Philippines
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.